Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · October 14, 2013

Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial
Lancet 2013 Oct 03;[EPub Ahead of Print], K Fitzgerald, M Frank-Kamenetsky, S Shulga-Morskaya, A Liebow, BR Bettencourt, JE Sutherland, RM Hutabarat, VA Clausen, V Karsten, J Cehelsky, SV Nochur, V Kotelianski, J Horton, T Mant, J Chiesa, J Ritter, M Munisamy, AK Vaishnaw, JA Gollob, A Simon

Further Reading